FBRX vs. ITRM, LSTA, RNXT, ONCT, UBX, APM, TXMD, ACST, BIOR, and BFRG
Should you be buying Forte Biosciences stock or one of its competitors? The main competitors of Forte Biosciences include Iterum Therapeutics (ITRM), Lisata Therapeutics (LSTA), RenovoRx (RNXT), Oncternal Therapeutics (ONCT), Unity Biotechnology (UBX), Aptorum Group (APM), TherapeuticsMD (TXMD), Acasti Pharma (ACST), Biora Therapeutics (BIOR), and Bullfrog AI (BFRG). These companies are all part of the "pharmaceutical preparations" industry.
Iterum Therapeutics (NASDAQ:ITRM) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, community ranking, valuation, earnings, dividends and media sentiment.
Iterum Therapeutics received 112 more outperform votes than Forte Biosciences when rated by MarketBeat users. Likewise, 62.27% of users gave Iterum Therapeutics an outperform vote while only 56.82% of users gave Forte Biosciences an outperform vote.
Forte Biosciences is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.
Iterum Therapeutics has a beta of 2.33, indicating that its stock price is 133% more volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500.
9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 5.4% of Iterum Therapeutics shares are owned by company insiders. Comparatively, 10.5% of Forte Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Iterum Therapeutics' return on equity of -99.44% beat Forte Biosciences' return on equity.
Iterum Therapeutics currently has a consensus price target of $6.00, indicating a potential upside of 325.53%. Forte Biosciences has a consensus price target of $2.75, indicating a potential upside of 357.57%. Given Iterum Therapeutics' higher possible upside, analysts clearly believe Forte Biosciences is more favorable than Iterum Therapeutics.
In the previous week, Forte Biosciences had 1 more articles in the media than Iterum Therapeutics. MarketBeat recorded 10 mentions for Forte Biosciences and 9 mentions for Iterum Therapeutics. Forte Biosciences' average media sentiment score of 0.55 beat Iterum Therapeutics' score of -0.10 indicating that Iterum Therapeutics is being referred to more favorably in the media.
Summary
Forte Biosciences beats Iterum Therapeutics on 8 of the 14 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding FBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Forte Biosciences Competitors List
Related Companies and Tools
